MK-0616 is smashing all competitors for the prevention and treatment of atherosclerosis.
Efficacy of antivirals and monoclonal antibodies for outpatient treatment of COVID-19 infection with the Omicron variant of SARS-CoV-2 coronavirus.
Teclistamab by Johnson & Johnson is a new hope for refractory or relapsing multiple myeloma.
One dose of AstraZeneca’s monoclonal antibody cocktail protects against COVID-19 for six months or longer.
Faricimab by Roche is a strong competitor to Eylea.
Tezepelumab is a powerful new drug for asthma, invented by Amgen and AstraZeneca, with a completely new mechanism of action.
Up-to-date scientific information about the new Omicron variant of SARS-CoV-2/COVID-19.